fbpx
previous arrow
next arrow
Slider

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Result of Placing

Manchester, UK – 5 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to confirm, further to the announcements made yesterday and earlier today, that all allocations have been confirmed by Nplus1 Singer Capital Markets Limited ("N+1 Singer"), and the Company  has raised gross proceeds of £16.15 million (approximately £15.0 million net of expenses) through a Placing of 95,000,000 new ordinary shares with certain existing and new institutional and other investors at the Placing Price of 17 pence per Placing Share.

Due to the strong demand received in market soundings and following the Bookbuild, the Company decided to increase the size of the Placing with additional funds being allocated to the acceleration of existing programs and other strategic growth initiatives. The Placing was oversubscribed against the Company’s original funding objective, resulting in net proceeds of approximately £15.0 million being raised for the Company. The Placing Price represents a 2.9 per cent. discount to the closing middle market price of 17.5 pence on 3 August 2020, being the latest practicable trading day prior to the announcement of the Placing.

N+1 Singer acted as sole bookrunner in connection with the Placing.

The Placing Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the Placing Shares.

Lyn Rees, Chief Executive Officer of Yourgene Health plc, commented:
“We are overwhelmed by the level of support we have seen from our existing and also new shareholders and I would like to extend my thanks to them all for enabling the acquisition of Coastal Genomics and facilitating further growth within the Company.  As an early adopter of this technology, which is now a crucial differentiator in our NIPT offering, we have got to know the team in Coastal Genomics and respect their capability and potential. This is a fantastic opportunity for Yourgene to expand our IP portfolio, grow our core technology and expand our geographical footprint and I am very optimistic about the prospect for the enlarged group to continue our growth journey with a stronger armour of IP and technology. The additional funds will be used to accelerate our R&D pipeline, expand our COVID-19 capacity, strengthen our commercial team in key regions and facilitate future M&A activity.”

Participation by Directors in the Placing
Certain of the Company's Directors (including Dr. Bill Chang, who is also a substantial shareholder) have agreed to subscribe for Placing Shares at the Placing Price.

The number of Placing Shares subscribed for by each of the Directors pursuant to the Placing, and their resulting shareholdings on Admission are set out below: 

Director

Number of existing Ordinary Shares

Number of Placing Shares subscribed for in the Placing

Number of Ordinary Shares held
on Admission

Percentage of enlarged
share capital
on Admission

Dr. Bill Chang

            74,855,996

                  510,000

            75,365,996

10.47%

Adam Reynolds

               5,449,656

                  100,000

               5,549,656

0.77%


Related party transactions

Dr. Bill Chang and Adam Reynolds (each a director of the Company) have participated in the Placing as set out above ("Transaction"), which pursuant to AIM Rule 13 is deemed to be a related party transaction. The Directors (excluding the Directors who are involved in the Transaction as related parties), having consulted with Cairn Financial Advisers LLP, the Company’s Nominated Adviser, consider that the terms of the Transaction are fair and reasonable insofar as the Company's shareholders are concerned.

Admission and dealings

Application has been made to the London Stock Exchange for the 95,000,000 Placing Shares to be admitted to trading on AIM. It is expected that Admission will occur and dealings will commence in the Placing Shares at 8.00 a.m. on 7 August 2020. The Placing is conditional upon, amongst other things, Admission becoming effective. The Placing is also conditional on the Placing Agreement not being terminated in accordance with its terms prior to Admission.

Conditional on Admission becoming effective and Completion, a further application will be made to the London Stock Exchange for the 178,753 Company Consideration Shares to be admitted to trading on AIM. It is expected that, admission of the Company Consideration Shares will occur and dealings will commence in such shares at 8:00am on 11 August 2020.

A further announcement is expected to be released by the Company upon Completion, both in respect of the Completion and of the intended admission of the Company Consideration Shares.

Total Voting Rights

Following Admission and the admission of the Placing Shares to trading on AIM, the Company's issued and fully paid share capital will consist of 719,331,197 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company will be 719,331,197. With effect therefrom, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Definitions
Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the announcement made by the Company on 4 August 2020 to announce the launch of the Placing.

For further information, please contact:

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Corporate Broker and Sole bookrunner)
Aubrey Powell / Tom Salvesen / George Tzimas

Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.



  • 21 October 2020 - Yourgene Genomic Services collaboration with Cytox +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services collaboration with Cytox

    Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer’s disease

    Manchester, UK – 21 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces a new collaboration between the recently launched Yourgene Genomic Services (“YGS”) and Cytox Ltd (“Cytox”), for a beta-testing genomic study on their

    Read More
  • 12 October 2020 - Elucigene DPYD tests to be used routinely in Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Elucigene DPYD tests to be used routinely in Wales

    Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapy
    DPYD tests screen patients to identify risk of severe side effects from certain chemotherapy treatments

    Manchester, UK – 12 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its oncology product, Elucigene DPYD test, is now being used in Wales to routinely

    Read More
  • 8 October 2020 - Strategic reproductive health partnership secured in Japan +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Strategic reproductive health partnership secured in Japan

    Manchester, UK – 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into a 5-year strategic partnership with a blue chip Japanese multinational to provide Yourgene’s Flex™ Analysis Software (“ Flex Software”) bioinformatics platform for a reproductive health project.

    Yourgene and the Japanese partner (the “Partner”) have entered into a technology transfer

    Read More
  • 7 October 2020 - IONA® Nx awarded contract with St George’s NHS Hospital +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    IONA ® Nx awarded contract with St George’s NHS Hospital

    Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the contract for non-invasive prenatal testing (NIPT) using its newly-launched IONA ® Nx NIPT Workflow ('IONA ® Nx'), by the prestigious St George’s NHS Trust Foundation in Tooting, South London (“St George’s”). The contract, subject to signing by both

    Read More
  • 28 September 2020 - Launch of Yourgene Genomic Services +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of Yourgene Genomic Services

    Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an integration and expansion of the Company’s international service laboratory offerings. Yourgene Genomic Services becomes a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations.

    Yourgene Genomic Services (“YGS”) will bring together

    Read More
  • 24 September 2020 - DPD reimbursement in Germany +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DPD reimbursement in Germany

    Manchester, UK – 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national reimbursement authority in Germany, has approved the reimbursement for testing of Dihydropyrimidine Dehydrogenase (DPD) deficiency in Germany, which opens up the clinical market in this region for the Company’s first oncology genotyping product, the Elucigene DPYD Test. The

    Read More
  • 22 September 2020 - AGM statement +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    AGM Statement

    Manchester, UK – 22 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting (AGM) at 4:00pm today.

    At the meeting, Adam Reynolds, Non-executive Chairman, will make the following statement:

    I am delighted to welcome longstanding and recent shareholders to our AGM. Whilst the pandemic has presented serious challenges to individuals, communities and businesses worldwide, these are

    Read More
  • 21 September 2020 - US distribution agreement for DPYD and other products +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    US distribution agreement for DPYD and other products

    Manchester, UK – 21 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has appointed Immuno-Biological Laboratories Inc (‘IBL-America’), a supplier of in-vitro diagnostic kits for the medical device and research industry, as a non-exclusive distributor for several PCR (‘polymerase chain reaction’) tests across Yourgene’s reproductive health and oncology portfolios in the US.

    The

    Read More
  • 3 September 2020 - IONA® Nx Launch +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    IONA ® Nx Launch

    Manchester, UK – 3 September 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA ® Nx NIPT workflow, the Company’s new innovative non-invasive prenatal test (‘NIPT’). The IONA Nx seeks to offer clinical labs a high performing, flexible, scalable and innovative NIPT service in-house and is developed to run on the Illumina Nextseq 550 Dx platform for next generation

    Read More
  • 13 August 2020 - TGA approves IONA® Nx for sale in Australia +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    TGA approves IONA ® Nx for sale in Australia

    Manchester, UK – 13 August 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its IONA ® Nx NIPT workflow (‘IONA ® Nx’), a non-invasive prenatal test (‘NIPT’), has been approved by Australia’s Therapeutics Goods Association (‘TGA’) as a medical device Class 3, allowing Southern Cross Diagnostics, Yourgene’s Australian distributor, to commence sales.

    The TGA is the regulatory

    Read More
  • 5 August 2020 - Result of Placing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Result of Placing

    Manchester, UK – 5 August 2020:  Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to confirm, further to the announcements made yesterday and earlier today, that all allocations have been confirmed by Nplus1 Singer Capital Markets Limited ( "N+1 Singer" ), and the Company  has raised gross proceeds of £16.15 million (approximately £15.0 million net of expenses) through a Placing of

    Read More
  • 5 August 2020 - Successful £16.15 million Placing & Close of Accelerated Bookbuild +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Successful £16.15 million Placing & Close of Accelerated Bookbuild

    Manchester, UK – 5 August 2020:  Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to announce that further to the announcement made yesterday at 5.13 p.m., the Bookbuild has now closed and following strong demand, the Company expects to raise gross proceeds of £16.15 million (approximately £15.0 million net of expenses) through the

    Read More
  • 4 August 2020 - Proposed Acquisition and Placing to raise a minimum of £13 million +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Proposed Acquisition and Placing to raise a minimum of £13 million

    Manchester, UK – 4 August 2020:  Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, today announces a proposed placing (the "Placing" ) of new ordinary shares of 0.1 pence each ( "Ordinary Shares" ) in the capital of the Company (the "Placing Shares" ) at a price of 17 pence per share (the "Placing Price") to raise

    Read More
  • 3 August 2020 - CE-IVD Mark for Clarigene™ SARS-CoV-2 test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    CE-IVD Mark for Clarigene™ SARS-CoV-2 test

    Manchester, UK – 3 August 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has achieved CE-IVD marking for its Clarigene™ SARS-CoV-2 in vitro diagnostic kit, for diagnostic use. The CE-IVD version of the Clarigene™ SARS-CoV-2 test will be used in Yourgene’s high throughput COVID-19 service lab in Manchester and will allow Yourgene to provide corporate

    Read More
  • 28 July 2020 - Final Results +

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

    Yourgene Health plc
    (“Yourgene”, the “Company” or the “Group”)

    Final Results

    Manchester, UK – 28 July 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its results for the year ended 31 March 2020.

    The results reflect strong organic growth as well as a first contribution from Elucigene Diagnostics (“Elucigene”), acquired in

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen